Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2025)

Historic Operating Leases for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Q3 2025 value amounting to $49.1 million.

  • Crinetics Pharmaceuticals' Operating Leases rose 890.4% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.1 million, marking a year-over-year increase of 890.4%. This contributed to the annual value of $44.6 million for FY2024, which is 627.69% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Operating Leases stood at $49.1 million for Q3 2025, which was up 890.4% from $43.3 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Operating Leases peaked at $49.1 million during Q3 2025, and registered a low of $1.5 million during Q2 2023.
  • Moreover, its 5-year median value for Operating Leases was $3.8 million (2021), whereas its average is $23.2 million.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 4323.59% in 2023, then surged by 305061.81% in 2024.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Operating Leases stood at $3.1 million in 2021, then crashed by 34.16% to $2.0 million in 2022, then skyrocketed by 2249.56% to $47.6 million in 2023, then decreased by 6.28% to $44.6 million in 2024, then rose by 10.26% to $49.1 million in 2025.
  • Its Operating Leases stands at $49.1 million for Q3 2025, versus $43.3 million for Q2 2025 and $43.9 million for Q1 2025.